Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553331 | 1.00 | GABRR1 (0.37) | GABRR1GABRR2BLMGABRR3LMNA | |
| SCHEMBL22442278 | 0.89 | MEN1 (0.35) | LMNAMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL248983 | 0.74 | MEN1 (0.38) | LMNAMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL1579916 | 0.72 | ALDH1A1 (0.35) | LMNAMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL246225 | 0.70 | MEN1 (0.34) | GABRR1LMNAMEN1HTTKMT2A | |
| SCHEMBL6228764 | 0.70 | MEN1 (0.34) | LMNAMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL17460039 | 0.69 | MEN1 (0.32) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL17460038 | 0.69 | MEN1 (0.32) | MEN1HTTKMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL12487855 | 0.68 | KDM4E (0.37) | BLMNPSR1MEN1HTTKMT2A | |
| Bicarbonate SCHEMBL4130664 | 0.68 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178851-B2 | Methods for administering STING agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-31 | — | — | US | disclosed |
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | STING1, CGAS, TLR9 | GABRR1 2151/4885GABRR2 1999/4885BLM 87/4885 |
| US-12178851-B2 | Methods for administering STING agonists | STING1, CGAS, TLR9 | GABRR1 2151/4885GABRR2 1999/4885BLM 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.